This website will be unavailable from Friday, April 26, 2024 at 6:00 p.m. through Monday, April 29, 2024 at 7:00 a.m. due to data center maintenance.

 
 
  By: Janek S.B. No. 625
 
 
 
   
 
A BILL TO BE ENTITLED
AN ACT
relating to restrictions on the interchange of transplant
immunosuppressant drugs.
       BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
       SECTION 1.  Subchapter A, Chapter 562, Occupations Code, is
amended by adding Section 562.0142 to read as follows:
       Sec. 562.0142.  TRANSPLANT IMMUNOSUPPRESSANT DRUG PRODUCT
SELECTION PROHIBITED.  (a)  In this section:
             (1)  "Immunosuppressant drug" means any drug
prescribed for immunosuppressant therapy following a transplant.
             (2)  "Interchange" means the substitution of one
version of the same immunosuppressant drug, including a generic
version for the prescribed brand, a brand version for the
prescribed generic version, a generic version by one manufacturer
for a generic version by a different manufacturer, a different
formulation of the prescribed immunosuppressant drug, or a
different immunosuppressant drug for the immunosuppressant drug
originally prescribed.
       (b)  Notwithstanding Section 562.014, a pharmacist may not
interchange an immunosuppressant drug or formulation of an
immunosuppressant drug, brand or generic for the treatment of a
patient following a transplant without prior notification of and
the signed informed consent of such interchange from the
prescribing physician.
       (c)  To comply with Subsection (b), a pharmacist may document
the notification of a prescribing physician and secure the informed
written consent of such physician by contacting the physician
orally or electronically to secure permission to interchange an
immunosuppressant drug or formulation of an immunosuppressant
drug, brand, or generic and reducing such consent to writing.  If
the prescribing physician does not authorize a substitute, such
denial shall also be documented in the same manner and format.  A
copy of such communication shall be forwarded to the physician and a
copy kept with the records of the pharmacist.  Such documented
notification and consent under this subsection shall be considered
a statement that the prescription is "brand medically necessary" 
and shall be considered part of the prescription, if applicable.
       SECTION 2.  Section 562.009, Occupations Code, is amended by
adding Subsection (e) to read as follows:
       (e)  If the prescription is for an "immunosuppressant drug" 
as defined in Section 562.0142(a)(1), the pharmacist must comply
with the provisions of Section 562.0142.
       SECTION 3.  This Act takes effect immediately if it receives
a vote of two-thirds of all the members elected to each house, as
provided by Section 39, Article III, Texas Constitution.  If this
Act does not receive the vote necessary for immediate effect, this
Act takes effect September 1, 2007.